Physician profile
Naomi G Habib
NPI 1639412034
$298,441.76
in general payments reported to CMS, 2019-2025
35 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $17.20 · 2021: $310 · 2022: $1,269 · 2023: $19K · 2024: $104K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Consulting Fee: $46K · Travel and Lodging: $30K · Food and Beverage: $15K · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,929.25 |
| Consulting Fee | $46,143.00 |
| Travel and Lodging | $30,448.10 |
| Food and Beverage | $14,701.13 |
| Education | $330.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $126,851.55 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $111,754.07 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $50,746.27 | 2022-2025 | Winrevair, Dificid, Keytruda |
| Chiesi USA, INC. | $5,332.90 | 2025 | |
| Inari Medical, INC. | $924.33 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Olympus America INC. | $305.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $235.05 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Sandoz INC. | $226.00 | 2023-2025 | Treprostinil |
| Grifols USA, LLC | $225.51 | 2022-2025 | Prolastin-C Liquid |
| Grifols Shared Services North America, INC. | $198.20 | 2024-2025 | Prolastin-C Liquid |
| Liquidia Technologies, INC. | $189.20 | 2025 | Yutrepia |
| Genentech USA, INC. | $141.07 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.76 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $133.00 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abiomed | $127.67 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.54 | 2023 | Krystexxa |
| Verona Pharma, INC. | $115.49 | 2025 | Ohtuvayre |
| Viiv Healthcare Company | $99.01 | 2024-2025 | Dovato, Rukobia |
| Insmed, INC. | $65.42 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $62.86 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.39 | 2023-2025 | Glassia, Hyqvia |
| Johnson & Johnson Health Care Systems INC. | $41.28 | 2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $40.44 | 2024 | Yupelri |
| Gilead Sciences, INC. | $38.94 | 2023 | Veklury |
| Philips North America LLC | $36.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.00 | 2023 | |
| Shionogi INC | $31.73 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $30.35 | 2019-2022 | |
| Abbvie INC. | $29.33 | 2022 | |
| Amgen INC. | $29.30 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $21.31 | 2023 | Dupixent |
| Janssen Biotech, INC. | $17.23 | 2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $17.04 | 2023 | |
| Baxter Healthcare | $15.21 | 2022 | |
| Oxford Immunotec USA INC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.